EBOS Group (EBO) AGM 2025 summary

Opening remarks and agenda

• Chair welcomed attendees in person and online, introduced directors, CEO, and CFO, and explained meeting logistics and structure, including year highlights, financial review, and formal business with four resolutions.

Financial performance review

• FY25 underlying revenue grew 12% to NZD 12.3 billion, with underlying EBITDA up 7.5% to NZD 585 million, in line with guidance and supported by organic growth and new customer wins.

• Statutory EPS declined 22.4% to 109.7 cps, with underlying EPS at 131.3 cps, mainly due to the loss of the Chemist Warehouse contract.

• Full-year dividend maintained at NZD 118.5 cps, payout ratio 83.8%, consistent with FY24.

• Net profit after tax was NZD 250 million on NZD 23.2 billion turnover, with margin pressure from high-cost medicines and competitive wholesale market.

• Growth objectives for FY25 were met, with strategic investments in distribution and acquisitions.

Board and executive committee updates

• CEO transition from John Cullity to Adam Hall, who commenced on 1 July 2025 after a global search for strategic and operational expertise.

• Coline McConville appointed as Non-Executive Director, bringing international governance and M&A experience.

• Board renewal ongoing, with five new directors since July 2021; six of seven are independent.